证券记录 · 已归档季度
PTCT
PTC Therapeutics, Inc. · Healthcare · Biotechnology
22被追踪持有人
+2Δ持有人
38.04M持有股份
$2.33B报告持仓市值
+2新建仓位
−0清仓
动量输入（同类管理人）：
持有人广度 +10.0% ·
股份流向 +3.1% ·
净新建仓位 +9.1%
· 公式
广泛增持：持股数量上升，持有人数量增加
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 18.67K | $1.18M | n/a | −1 |
| Q2 2026 | 113 | +8 | 59.00M | $4.80B | +13 | −7 |
| Q1 2026 | 110 | -8 | 65.31M | $4.45B | +9 | −18 |
| Q4 2025 | 117 | 0 | 67.93M | $5.16B | +1 | n/a |
| Q3 2025 | 22 | +2 | 38.04M | $2.33B | +2 | n/a |
| Q2 2025 | 17 | 0 | 34.63M | $1.69B | +1 | −1 |
| Q1 2025 | 14 | +2 | 16.93M | $862.87M | +2 | n/a |
| Q4 2024 | 12 | 0 | 14.84M | $670.12M | n/a | n/a |
| Q3 2024 | 11 | -2 | 14.00M | $519.42M | n/a | −2 |
| Q2 2024 | 13 | n/a | 14.28M | $436.54M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 8.29M | -6.3% | $508.70M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 7.13M | -4.7% | $437.62M | 0.0% | ▼ Trim | 2 | SEC ↗ ×18 |
| 3 | Wellington Management ✦ | 4.92M | +4.8% | $301.86M | 0.1% | ▲ Add | 6 | SEC ↗ ×8 |
| 4 | State Street Global Advisors ✦ (被动) | 3.13M | +4.6% | $192.38M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | D. E. Shaw & Co. ✦ | 2.17M | -10.8% | $133.46M | 0.1% | ▼ Trim | 6 | SEC ↗ ×3 |
| 6 | Geode Capital Management ✦ (被动) | 1.95M | +0.8% | $119.74M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 1.73M | +88.0% | $106.23M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 1.61M | -6.2% | $98.91M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 9 | Point72 Asset Management ✦ | 1.22M | 新增 | $74.91M | 0.2% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.06M | +174.8% | $64.84M | 0.1% | ▲ Add | 6 | SEC ↗ |
| 11 | JPMorgan Chase ✦ | 981.87K | n/a | $60.26M | 0.0% | n/c | 1 | SEC ↗ ×18 |
| 12 | Renaissance Technologies ✦ | 927.30K | -3.7% | $56.91M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 13 | Goldman Sachs Group ✦ | 876.41K | n/a | $53.79M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | T. Rowe Price ✦ | 458.33K | +1.0% | $28.13M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | Morgan Stanley ✦ | 419.42K | n/a | $25.74M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 16 | AQR Capital Management ✦ | 331.26K | -38.3% | $20.33M | 0.0% | ▼ Trim | 6 | SEC ↗ ×4 |
| 17 | Arrowstreet Capital ✦ | 323.55K | +851.6% | $19.86M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 18 | Adage Capital Partners ✦ | 291.00K | -52.0% | $17.86M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | Marshall Wace ✦ | 157.74K | -70.7% | $9.68M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 20 | Two Sigma Investments ✦ | 24.34K | -52.1% | $1.49M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 21 | Gotham Asset Management ✦ | 18.06K | -49.3% | $1.11M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 22 | Bridgewater Associates ✦ | 11.94K | 新增 | $732,635 | 0.0% | New | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Point72 Asset Management | $74.91M | 0.2% |
| Bridgewater Associates | $732,635 | 0.0% |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 348 持有人, 95.15M 股份, $6.33B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Oct 14
SCHMERTZLER MICHAEL
Director · 382 股 · $22,973
Oct 14
SCHMERTZLER MICHAEL
Director · 2.12K 股 · $126,063
Oct 09
Boulding Mark Elliott
Officer · 192 股 · $12,338
Oct 07
SCHMERTZLER MICHAEL
Director · 2.45K 股 · $155,091
Oct 07
SCHMERTZLER MICHAEL
Director · 53 股 · $3,389
Oct 06
Boulding Mark Elliott
Officer · 435 股 · $27,910
Oct 05
Boulding Mark Elliott
Officer · 1.64K 股 · $104,881
Sep 17
SCHMERTZLER MICHAEL
Director · 376 股 · $25,737
Sep 17
SCHMERTZLER MICHAEL
Director · 9.62K 股 · $652,796
Sep 16
SCHMERTZLER MICHAEL
Director · 7.01K 股 · $471,854
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据